Fennec Pharmaceuticals (TSE:FRX) Rating Increased to Strong-Buy at Stephens

Stephens upgraded shares of Fennec Pharmaceuticals (TSE:FRX) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports.

Fennec Pharmaceuticals Stock Performance

Shares of TSE FRX opened at C$6.59 on Monday. The business’s 50-day moving average price is C$6.40 and its two-hundred day moving average price is C$7.99. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. Fennec Pharmaceuticals has a one year low of C$5.65 and a one year high of C$15.43. The company has a market capitalization of C$180.30 million, a P/E ratio of 64.70 and a beta of 0.25.

Insiders Place Their Bets

In related news, Senior Officer Robert Christopher Andrade purchased 15,816 shares of Fennec Pharmaceuticals stock in a transaction on Monday, November 18th. The stock was bought at an average price of C$3.43 per share, with a total value of C$54,248.88. Insiders sold 6,268 shares of company stock valued at $42,990 over the last quarter. Insiders own 16.20% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.